These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38752352)

  • 21. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
    Beghetti M; Rudzinski A; Zhang M
    BMC Cardiovasc Disord; 2017 Jul; 17(1):177. PubMed ID: 28676038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.
    Chanu P; Gao X; Bruno R; Claret L; Harnisch L
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):499-509. PubMed ID: 31538282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.
    Roustit M; Giai J; Gaget O; Khouri C; Mouhib M; Lotito A; Blaise S; Seinturier C; Subtil F; Paris A; Cracowski C; Imbert B; Carpentier P; Vohra S; Cracowski JL
    Ann Intern Med; 2018 Nov; 169(10):694-703. PubMed ID: 30383134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sildenafil improves renal function in patients with pulmonary arterial hypertension.
    Webb DJ; Vachiery JL; Hwang LJ; Maurey JO
    Br J Clin Pharmacol; 2015 Aug; 80(2):235-41. PubMed ID: 25727860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
    Bermejo J; Yotti R; García-Orta R; Sánchez-Fernández PL; Castaño M; Segovia-Cubero J; Escribano-Subías P; San Román JA; Borrás X; Alonso-Gómez A; Botas J; Crespo-Leiro MG; Velasco S; Bayés-Genís A; López A; Muñoz-Aguilera R; de Teresa E; González-Juanatey JR; Evangelista A; Mombiela T; González-Mansilla A; Elízaga J; Martín-Moreiras J; González-Santos JM; Moreno-Escobar E; Fernández-Avilés F;
    Eur Heart J; 2018 Apr; 39(15):1255-1264. PubMed ID: 29281101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study.
    Omarjee L; Le Pabic E; Custaud MA; Fontaine C; Locher C; Renault A; Jaquinandi V; Azzola V; Barbeau-Terrier C; Laporte I; Ripoche M; Onillon Y; Chretien JM; Daniel V; Chao de la Barca JM; Homedan C; Reynier P; Abraham P; Mahé G
    Vascul Pharmacol; 2019; 118-119():106563. PubMed ID: 31152977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
    Yasuhara J; Watanabe K; Watanabe A; Shirasu T; Matsuzaki Y; Watanabe H; Takagi H; Sumitomo N; Kuno T
    Cardiol Young; 2023 Nov; 33(11):2297-2311. PubMed ID: 36721907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
    Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
    J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sildenafil for the treatment of pulmonary hypertension in children.
    Beghetti M; Wacker Bou Puigdefabregas J; Merali S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1157-84. PubMed ID: 25223406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
    Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
    Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sildenafil for pulmonary hypertension in neonates.
    Kelly LE; Ohlsson A; Shah PS
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005494. PubMed ID: 28777888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
    Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of pulmonary arterial hypertension using extemporaneous formulation of sildenafil in Mexican children.
    Juárez Olguín H; Camacho Reyes L; Roldan Arce A; Calderón Guzmán D
    Pediatr Cardiol; 2015 Jun; 36(5):1019-23. PubMed ID: 25612785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil].
    Franchi SM; Barreto AC; Cícero C; Castro CR; Ribeiro ZV; Lopes AA
    Arq Bras Cardiol; 2010 May; 94(5):671-7. PubMed ID: 20428715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.
    Abman SH; Kinsella JP; Rosenzweig EB; Krishnan U; Kulik T; Mullen M; Wessel DL; Steinhorn R; Adatia I; Hanna B; Feinstein J; Fineman J; Raj U; Humpl T;
    Am J Respir Crit Care Med; 2013 Mar; 187(6):572-5. PubMed ID: 23220921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.